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Summary Four patients underwent intraoperative photodynamic therapy after surgery with meso-tetra-
(hydroxyphenyl)-chlorin (mTHPC-PDT) for diffuse malignant mesothelioma. Preliminary procedures were
performed in two patients in order to establish the efficacy of mTHPC-PDT and to optimise its tumoricidal
effect. The tumoricidal effect was related to the mTHPC dose, light dose and the time interval between
sensitation and activation. 0.3 mg kg-' mTHPC activated after 48 h with 10 Joules cm-2 of non-thermal laser
light at 650 nm resulted in a 10 mm deep tumour infarction, due to tumour vessel necrosis and thrombosis.
The mTHPC tissue concentration was up to 14 times higher in the tumour than in normal tissues. Skin
photosensitivity was mild, dose dependent and occurred 3 to 10 days after administration of mTHPC.
According to the results obtained, intraoperative mTHPC-PDT was performed following pleuropneumonec-
tomy in two, pleurectomy and lobectomy in one and pleurectomy in one patient. Ten Joules cm 2 were
delivered to the diaphragm and the costophrenic sulcus and 5 Joules cmn2 to the remaining thoracic cavity.
The postoperative course was marked by loss of appetite, fluid retention, hypoproteinemia and severe chest
pain. One patient succumbed from aspiration pneumonia. The remaining patients developed no neural or
vascular alterations and no bronchial stump insufficiency during follow-up. mTHPC-PDT following surgical
tumour resection deserves further evaluation in good risk patients with diffuse malignant mesothelioma.
Diffuse malignant mesothelioma spreads on pleural and peri-
toneal surfaces with invasion of the underlying structures,
first of all of the diaphragm. There is no cure at present.
Patients succumb in general from relentless local progression
of the disease regardless of the treatment performed and not
from distant metastatic spread, indicating that local control
is not effective even if extended resections have been per-
formed (Faber, 1988). Improved local control does require
additional measures, but the disease responds poorly to
radio- and chemotherapy (Lerner et al., 1983). As photo-
dynamic therapy (PDT) has been reported to be effective in
human mesothelioma xenografts (Feins et al., 1990), it might
allow for an appropriate 'clean-up' of the thoracic cavity
after surgery. For clinical purposes, the currently used sen-
sitisers for PDT are haematoporphyrin derivatives (HpD)
and dihaematoporphyrin ether (DHE) (Dougherty et al.,
1990). However, PDT with meso-tetra-(hydroxyphenyl)-chlo-
rin (mTHPC) was superior to DHE-PDT with respect to
antitumour activity and tissue selectivity in rodents without
causing significant toxicity (Berenbaum, 1989). mTHPC
might therefore be better fitted to large surface PDT as
required for diffuse malignant mesothelioma treatment. A
pilot study was done to evaluate mTHPC-PDT for diffuse
malignant mesothelioma with respect to its antitumour
activity and the feasibility of a combined modality approach
under clinical conditions.
Patients and methods
Four patients underwent mTHPC-PDT for diffuse malignant
mesothelioma. Each patient was informed in detail about the
experimental nature of the procedure and consent was
obtained from each patient and from the local Human
Investigations Committee of our institution.
The four men were aged 46 (patient 1), 48 (patient 2), 65
(patient 3) and 50 years (patient 4), all having had possible
occupation related exposure to asbestos. The main symptoms
at admission were dyspnoea due to pleural effusion, chest
pain and loss of weight. There was no evidence of disease in
the peritoneal and contralateral chest cavity on CT-scans at
admission. The right side was involved in patients 1, 2 and 4
and the left in patient 3. Previous biopsies revealed an epithe-
lial (Figure la), a biphasic (Figure 2a), a sarcomatous and a
mixed type of mesothelioma in the four patients and was
confirmed in every case by immunohistologic examinations.
Preliminary PDT
To establish the efficacy of mTHPC-PDT and to optimise its
tumouricidal effect, preliminary PDT was performed in
patients 1 and 2 prior to its definitive application. Modula-
tions of mTHPC dose, light dose and of the time interval
between mTHPC application and activation were tested.
mTHPC (Scotia Pharmaceuticals Ltd, Guildford, UK) was
dissolved in 20% ethanol, 30% polyethylene glycol 400 and
50% H20 and administered over 15 min i.v. through a
bacterial filter under sterile conditions within 60 min of pre-
paration. Argon-pumped dye laser light of 650 nm (Coherent
Innova 200 and Dye CR 599, GMP SA, Lausanne, Switzer-
land) was delivered through a sterilised optical fibre on
tumour areas of 3 cm diameter. The power at the end of the
optical fibre was measured witha power meter, allowing for
a power density of 0.1 Wattcm2 on the treated surfaces
(non-thermal surface irradiation). No protection of the skin
from the operating theatre lights was performed. Normal
light sources were used for laryngoscopy and bronchoscopy
during double lumen intubation which was performed for
each procedure. Five days after the light delivery the areas
were biopsied and the histologic specimen compared to those
of the untreated areas. Light delivery and biopsy procure-
ment were performed on both patients twice by thoracoscopy
and once through a small thoracotomy to obtain exact irrad-
iance geometry and a cross sectional profile of the PDT
related tumour destruction. The time interval between the
three PDT was 3 weeks. mTHPC plasma concentrations were
measured at regular intervals by high performance liquid
chromatography up to 9 days after administration. Patients
were cautioned to avoid direct sunlight for about 2 weeks but
were encouraged to test skin sensitivity by daily exposure of
the hand for a short period of time.
Correspondence: H.-B. Ris, Klinik fur Thorax- Herz- und Gefass-
chirurgie, Inselspital, 3010 Bern, Switzerland.
Received 7 June 1991; and in revised form 13 August 1991.
Br. J. Cancer (I991), 64, 1116 1120 '." Macmillan Press Ltd., 1991mTHPC-PHOTOCHEMOTHERAPY FOR MALIGNANT MESOTHELIOMA 1117
a
b
Figure 1 Photodynamic therapy with mTHPC for diffuse malig-
nant mesothelioma: a, Morphology of the untreated tumour of
patient 1; b, Tumour.infarction due to tumour vessel necrosis and
thrombosis after 0.075 mg kg-' mTHPC and 10 Joules cm2,
time interval 24 h; c, 10 mm deep tumour necrosis in the centre
and the periphery of the treated area after 0.3 mg kg-' mTHPC
and 10 Joules cm-2, time interval 48 h. The specimens for
histology were taken 5 days after PDT (Haematoxylin-Eosin,
bar = 200jsm).
Intraoperative PDTfollowing surgery
According to the results obtained from preliminary PDT,
intraoperative PDT following surgical tumour resection was
performed with 0.3 mg kg-' mTHPC administered 48 h prior
to light delivery in all four patients. The surgical procedure
consisted of an extrapleural pneumonectomy in patients 1
and 2, a pleurectomy in patient 3 and a pleurectomy with
resection of the lower lobe in patient 4. A cleavage plain
between normal tissue and tumour was found in patients 1
and 2 at the chest wall and the mediastinum, and in patient 4
at the chest wall, the mediastinum and the upper lobe. No
reasonable plain was found at the chest wall, the media-
stinum and the lung in patient 3 with a sarcomatous type of
Figure 2 Photodynamic therapy with mTHPC for diffuse malig-
nant mesothelioma: a, Morphology of the untreated tumour of
patient 2; b, Balloonated basophilic tumour cells of questionable
viability and prominent interstitial edema after 0.15 mg mTHPC
kg-' and 2 Joulescm2, time interval 24h. The specimens for
histology were taken 5 days after PDT. (Haematoxylin-Eosin,
bar = 200jtm).
tumour. The diaphragm was debulked yet preserved in all
four patients in order to keep intact this natural barrier to
the peritoneal cavity. The pericardium was removed in
patient 1 and 2, preserved in patient 3 and partially removed
and replaced by a vicryl mesh in patient 4. After the resec-
tion, the light was delivered through the open chest wound,
with a dose of 10 Jcm2 to the diaphragm and the costo-
phrenic sulcus and of 5 J cm-2 to the remaining cavity (in-
cluding the lung in patients 3 and 4). The diameters of the
light spots varied from 5 to 12 cm, according to the geometry
of the area treated. To reduce additional loss of energy and
divergence of the laser beam, the light was delivered through
a bare fibre rather than a lens. The spots were therefore
overlapped to prevent unequal light distribution by the bare
fibre. The maximal laser power output at the end of the fibre
was 1.5 Watt in patient 1, 2 and 3. Patient 4 was treated by a
new high power laser system, allowing for 4 Watt at the end
of the fibre at 650 nm. The heart was shielded from direct
irradiance by a moist towel in patients 1 and 2. mTHPC
concentrations were measured in the tumour and in normal
tissues 48 h after mTHPC-administration.
Results
Preliminary PDT
Tumour response to mTHPC-PCT 0.075mgkg-' mTHPC
and 10Joules cm-2 delivered after 24 h resulted in frank
necrosis of approximately 50% of tumour on semi-serial
sections investigated from treated areas (diameter of biopsy
b
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specimen: 10 mm). The histologic pattern of necrosis was
consistent with tumour infarction. Tumour vessels showed a
fibrinoid necrosis of the vessel wall and thrombosis. The
tumour necrosis extended from the vascular watershed to-
wards the vessels whereas the remaining 50% of tissue
around the vessels appeared edematous and possibly viable
(perivascular sparing, Figure lb). Specimens taken from un-
treated tumour areas served as controls and showed no
spontaneous tumour necrosis (Figure la).
0.15 mg mTHPC kg-' activated after 24 h with 10 Joules
cm 2 resulted in a 50% to 80% infarction related tumour
destruction. However, balloonated basophilic tumour cells of
questionable viability and prominent interstitial edema were
observed with 0.15 mg mTHPC kg ' and 2 Joulescm2
delivered after 24 h (Figure 2b). No spontaneous tumour
necrosis was found in biopsy specimens from adjacent but
untreated tumour areas (Figure 2a).
0.3 mg mTHPC kg-' and 10 Joules cm2 delivered after
24 h resulted in a 1Omm deep complete tumour necrosis in
the centre but with preserved cells in the periphery of the
treated areas. No viable tumour cells were observed in the
periphery when the same light dose was applied after 48 h
(Figure Ic). Higher light doses (up to 40 Joules cm-2) did not
lead to deeper tumour destruction than that observed with
10 Joules cm-2.
Skin photosensitivity The only side effect observed after
mTHPC administration was a mild, dose dependent skin
photosensitivity. It appeared 3 to 10 days after administra-
tion of mTHPC and lasted for 2 to 3 days. Photosensitivity
was observed after direct and indirect (closed window) expo-
sure to sunlight, but not under normal room light conditions.
No adverse effect was observed from the operating theatre
lights nor from the lights used for laryngoscopy and bron-
choscopy during double lumen intubation, although these
lights contain a high percentage of red light.
mTHPCplasma, urine and tissue concentrations Plasma con-
centrations followed a first order kinetics after i.v. applica-
tion and the half-life time was 12 h. An average plasma
concentration of 14.6 ± 7.6fig 100 ml-' was measured 48 h
after administration of 0.3 mg mTHPC kg-'. At this time,
the mTHPC concentration in the tumour was 1.41tgg-', in
the bronchus, pulmonary artery and pulmonary vein wall of
the resected specimen 0.21tgg-', 0.3;gg-' and 0.1ILgg-'
and in muscle and skin tissue 0.21gg-' and 0.1 pgg-'
respectively.
Nine days after administration, mTHPC was still detect-
able in the plasma (4tLg 100ml-'). No mTHPC or metabo-
lites were identified in urine samples at any time.
Intraoperative PDTfollowing surgery
An additional 2 h were required for PDT of the thoracic
cavity in patients 1, 2 and 3 after completion of the surgical
tumour resection. Appropriate exposure of the costophrenic
sulcus was obtained by manual retraction of the diaphragm.
Difficulties were encountered in ensuring equal and sufficient
light distribution to the anterior chest wall in these three
patients and to the entire surface of the collapsed lung in
patient 3. Patient 4 was treated with a new high power laser
system and the overall PDT treatment time was reduced to
50 min. Appropriate light delivery to the costophrenic sulcus,
the anterior chest wall and to the remnant lung was much
easier in this patient due to the markedly reduced treatment
time.
Postoperative course Loss of appetite, fluid retention (up to
8 kg), hypoproteinemia (50.4 ± 7 g1'-l) and more severe chest
pain than anticipated from the surgical procedure per se were
specific side effects following this combined approach. Serum
cre-ktinine values and urine output were normal throughout.
SGOT, SGPT and alkaline phosphatase values were slightly
increased in the first postoperative days, but did not exceed
3-fold of the normal range. CK values were not higher than
after surgery per se (1,000 U -') in patients 1, 2 and 3;
however, they were increased in patient 4 (3,800 U 1'). The
CK-MB fraction was not increased in any patient. The chest
pain was controlled by opiods or peridural analgesia and
disappeared after about 1 week. Retained fluids were spon-
taneously mobilised 3 to 5 days after the operation. The
clinical course in patient 4 did not differ from that in patients
1 and 2, despite the higher power density applied in this
patient.
Patients 1, 2 and 4 were discharged after 3 weeks, but
patient 3 succumbed from a massive aspiration induced
pneumonia of his contralateral lung on the sixth post-
operative day. The autopsy revealed PDT induced necrosis of
the remnant tumour throughout the chest cavity and the lung
surface. The depth ofnecrosis, however, varied with the area
treated, and ranged from 0.5 to 1 cm at the diaphragm
(Figure 3a) and the costophrenic sulcus and from 0.3 to
0.5 cm at the remaining sites of the cavity, including the lung
surface. Even in the presence of full thickness necrosis of the
adjacent tumour, underlying structures such as the aorta,
nerve ganglion cells and the oesophagus were spared (Figure
3b and 3c). However, chondrocytes and osteocytes ofthe ribs
and smooth muscle cells of the aorta adjacent to the destroy-
ed tumour were also altered, due to PDT induced damage of
nutritive vessels (Figure 3d). The lung showed small foci of
subpleural alveolitis under the destroyed tumour.
Follow-up No insufficiency of the bronchial stump and no
vascular alterations were observed in the remaining three
patients during follow-up. Patient 2 showed a diffuse weak-
ness of his right arm without evidence of a lesion of the
peripheral nerves, however. CT-scans revealed no structural
alterations of the mediastinal organs 3 months after the
operation. There was no evidence of disease in patients 2 and
4 on CT-scans at the time, however, patient 1 showed contra-
lateral disease and anterior chest wall invasion at a previous
biopsy site.
Discussion
The goal of PDT is selective tumour eradication whilst spar-
ing adjacent normal tissue. A sensitiser with preferential
uptake by tumour tissue is administered and activated by a
non-thermal dose of laser light of a specific wavelength,
leading to free radical formation and destruction of the
target tissue. Intraoperative PDT of a tumour bed following
surgery is a promising concept for tumours not removable
with the required margins of tumour-free tissue. Pilot studies
have been done in this respect with HpD and DHE for
retroperitoneal sarcomas (Nambisan et al., 1987), residual or
recurrent colorectal cancer in the pelvis (Herrera-Ornelas et
al., 1985), diffuse malignant mesothelioma (Pass et al., 1990;
Lofgren et al., 1991) and for disseminated intraperitoneal
malignancies (Sindelar et al., 1991). The results of these
studies indicate that large surface PDT is feasible: however,
the tumouricidal effect for intraoperative large surface PDT
has not been proven in these reports. Moreover, the delivered
light dose ranged from 3 to 400 Joules cm-2 and the optimal
dose still needs to be clarified. A major hindrance in treating
large surfaces is their irregular geometry which renders
uniform light delivery difficult. Efficacy and tumour selec-
tivity of PDT are crucial for this purpose. Both depend on
the sensitiser used and, according to the given sensitiser, on
the interplay of its dose, the light dose and the time interval
between application and activation. To overcome the short-
comings of HpD and DHE, new sensitisers have been
developed with improved properties in this respect (Pandey et
al., 1991). Among chlorins, mTHPC has shown excellent
tumour eradication and tissue selectivity in rodents, requiring
only 10 Joulescm-2 to induce tumour necrosis of 0.6cm
depth, and without apparent side effects and minimal skin
sensitivity (Berenbaum et al., 1989). Furthermore, mTHPC
strongly absorbs at 650 nm. This wavelength penetrates tissue
better than that required for HpD or DHE activation. ThemTHPC-PHOTOCHEMOTHERAPY FOR MALIGNANT MESOTHELIOMA 1119
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Figure 3 Combined modality approach for diffuse malignant mesothelioma. Autopsy findings in patient 3, 6 days after PDT: a 5
to 10 mm deep necrosis of the tumour invading the diaphragm (bar = 2 mm); b, destroyed tumour with preservation of an
underlying nerve ganglion (*fixation related artifact, bar = 200 JAm); c, destroyed tumour invaded the aorta with preservation of the
vessel wall (bar = 2 mm); d, altered smooth muscle cells of the aorta adjacent to destroyed invading tumour (bar = 200 JLm)
(Haematoxylin-Eosin).
effective penetration depth steeply increase in soft tissues
between 600 and 650 nm (Wilson & Patterson, 1990). Our
initial clinical results demonstrate a preferential uptake of
mTHPC in tumour tissue. The mTHPC concentration was
up to 14 times higher in the tumour than in the skin and
other normal tissues. In contrast, for HpD and DHE a 2 to 4
ratio of tumour to skin concentration was reported (Gomer
& Dougherty, 1979; Moan et al., 1987). Furthermore, a light
dose of 10 Joules cm-2 caused a 10 mm deep tumour necrosis
after administration of 0.3 mg kg- mTHPC to our patients.
This efficacy has not been reported for DHE- or HpD-PDT.
In addition, the only side effect caused by this mTHPC dose
was a mild skin sensitivity of shorter duration than observed
after HpD or DHE application. Patients have to avoid out-
door sunlight for about 10 days after administration of
mTHPC, as opposed to at least 1 month after HpD and
DHE application.
As expected from previous results (Nelson et al., 1990),
tumour vessels seem to be the primary target for mTHPC-
PDT, leading to necrosis of the vessel wall, thrombosis and
subsequent tumour infarction (Figure lb). However, the
different morphology obtained after low light doses (Figure
2b) suggests a different mechanism of action and may be
related to direct cell alteration by PDT.
Our results indicate that the tumouricidal effect depends
on mTHPC dose, light dose and the time interval between
sensitation and activation. Small mTHPC and light doses
and a shorter time interval resulted in decreased tumour
destruction. Variations of mTHPC short dose had a greater
impact in this respect than variations of light dose. However,
the optimal configuration has yet to be defined. It was
noteworthy that the autopsy findings showed no adverse
altering ofthe PDT-induced tumouricidal effect by previously
performed debulking surgery.
Although exposed to the same light dose as the remnant
tumour, the apparent absence of extensive muscle necrosis
and of damage to the bronchial, vascular and neural struc-
tures suggest some reasonable degree of treatment selectivity
for mTHPC-PDT under clinical conditions. However, the
large surface treatment caused substantial additional burden
to the patients in the postoperative course. The autopsy
findings also raised concern about what degree normal tissue
can be spared in the case of invading tumours. Although
normal tissue damage was restricted to a few cell layers
bordering the destroyed tumour, these results indicate further
attention should be paid towards late sequelae of the involv-
ed underlying structures. Decreasing the mTHPC dose
while increasing the light dose might improve tissue selec-
tivity, as has been reported of DHE-PDT (Dougherty et al.,
1990).
Sufficient and uniform light delivery to all areas of the
large and complex shaped thoracic cavity without exceeding
a reasonable overall treatment time is mandatory for PDT of
diffuse malignant mesothelioma. A high power laser system is
now available, allowing for 4 Watt power output at the end
of the treating fibre at 650 nm, with Kiton Red as dye. As
shown in patient 4, this reduces the overall treatment time
required for PDT to less than 1 h and does not increase
morbidity despite the higher power density applied. Sophis-
ticated light delivery devices (DeLaney et al., submitted for
publication) and continuous light monitoring with cumulative
recording of the delivered light dose (Friauf et al., submitted
for publication) will further contribute to uniform and
appropriate light delivery.
mTHPC-PDT following surgical tumour resection deserves
further evaluation in good risk patients with diffuse malig-
nant mesothelioma.
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